Interleukin-22-induced β‑defensin-2 expression by intranasal immunization with Streptococcus pneumoniae RrgB epitopes

Main Article Content

Diana Chusna Mufida
https://orcid.org/0000-0001-7197-9816
Antonius Dwi Saputra
https://orcid.org/0000-0001-7356-6732
Bagus Hermansyah
https://orcid.org/0000-0002-0946-2936
Dini Agustina
https://orcid.org/0000-0002-1861-0056
Muhammad Ali Shodikin
https://orcid.org/0000-0002-8216-3609
Yunita Armiyanti
https://orcid.org/0000-0001-6998-750X

Abstract

Background
Streptococcus pneumoniae causes pneumococcal disease, which is responsible for millions of deaths worldwide. Various pneumococcal vaccine candidates have been developed to prevent S. pneumoniae infection, one of which is an epitope-based vaccine. This study aimed to prove that intranasal immunization with each of the five S. pneumoniae RrgB epitopes can induce a mucosal immune response by increasing the β-defensin-2 concentration through upregulation of interleukin (IL)-22 expression.


Methods
An experimental laboratory study was conducted using 28 male Wistar rats aged 3-4 months, that were randomly divided into 7 groups containing four rats each. Group 1 was given 40 mL of phosphate-buffered saline (PBS) only (control group). Group 2 was the adjuvant group that received 40 mL PBS containing 2 ìg cholera toxin B (CTB), and groups 3-7 were immunized with 40 mL PBS containing a combination of adjuvant and one of the five different S. pneumoniae RrgB epitopes. The concentrations of IL-22 and β-defensin-2 from nasal rinse examination were measured by means of ELISA. The Kruskal-Wallis test, followed by the Mann-Whitney post-hoc test were used for statistical analysis.


Results
Rats immunized with the adjuvant-epitope combination had significantly higher β-defensin-2 and IL-22 levels than the control group (p=0.030; p=0.018, respectively), according to the Kruskal-Wallis test. And the Mann-Whitney statistical test, showed there was a significant increase in β-defensin-2 and IL-22 levels.


Conclusions
Intranasal immunization with epitope 1 of the S. pneumoniae RrgB can increase β-defensin-2 expression significantly and has a greater potential to be developed into a pneumococcal vaccine.

Article Details

How to Cite
Mufida, D. C., Saputra, A. D., Hermansyah, B., Agustina, D., Shodikin, M. A. ., & Armiyanti, Y. . (2022). Interleukin-22-induced β‑defensin-2 expression by intranasal immunization with Streptococcus pneumoniae RrgB epitopes. Universa Medicina, 41(1), 37–46. https://doi.org/10.18051/UnivMed.2022.v41.37-46
Section
Original Articles

References

Eze UA, Mustapha A, Nworie A. Streptococcus pneumoniae:: virulence factors and their role in pathogenesis. Cont J Med Res 2013;7:27–45. doi:10.5707/cjmedres.2013.7.1.27.45.

Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol 2018;16:355-67. doi: 10.1038/s41579-018-0001-8.

Brooks LRK, Mias GI. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol 2018;9 : 1-29. | https://doi.org/10.3389/fimmu.2018.01366.

Chang MS, Woo JH. The prevention of pneumococcal infections. Clin Exp Vaccine Res 2016;5:3. doi: 10.7774/cevr.2016.5.1.3.

Masomian M, Ahmad Z, Gew LT, Poh CL. Development of next generation streptococcus pneumoniae vaccines conferring broad protection. Vaccines 2020;8:1–23. doi: 10.3390/vaccines8010132.

Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 2015;28:871–99. doi: 10.1128/CMR.00024-15.

Lei Y, Zhao F, Shao J, et al. Application of built-in adjuvants for epitope-based vaccines. Peer J 2019; 6: e6185. doi: 10.7717/peerj.6185.

Xu Y, Yuen P-W, Lam J. Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives. Pharmaceutics 2014;6:378–415. doi: 10.3390/pharmaceutics6030378.

Mufida DC, Handono K, Prawiro SR, Santoso S. Identification of hemagglutinin protein from Streptococcus pneumoniae pili as a vaccine candidate by proteomic analysis. Turkish J Immunol 2018;6:8–15. DOI: 10.25002/tji.2018.742.

Trevejo-Nunez G, Elsegeiny W, Aggor FEYY, et al. Interleukin-22 (IL-22) binding protein constrains IL-22 activity, host defense, and oxidative phosphorylation genes during pneumococcal pneumonia. Infect Immun 2019;87:e00550-19. doi: 10.1128/IAI.00550-19.

Tsai HC, Wu R. Mechanisms of cholera toxin in the modulation of TH17 responses. Crit Rev Immunol 2015;35:135-52. doi: 10.1615/critrevimmunol.2015012295.

Mcaleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev 2014 ;260:129-44. doi: 10.1111/imr.12183.

Widiatmaja DT, Mufida DC, Febianti Z. Pengaruh pemberian imunisasi intranasal ppitope protein RrgB 255-270 Streptococcus pneumoniae terhadap kadar IL-4. Sriwijaya J Med 2021;4:67–73.

Mufida DC, Agustina D, Armiyanti Y, Handono K, Prawiro SR, Santoso S. Intranasal immunization with the 54 kDa hemagglutinin pili protein of Streptococcus pneumoniae that increase the expression of β-defensin-2. Drug Invention Today 2019;11:2609–15.

Scharf S, Zahlten J, Szymanski K, Hippenstiel S, Suttorp N, N’Guessan PD. Streptococcus pneumoniae induces human β-defensin-2 and-3 in human lung epithelium. Exp Lung Res 2012;38:100-10. doi: 10.3109/01902148.2011.652802.

Díaz MF, Calderon K, Rojas-Neyra A, et al. for the COVID-19 Working Group in Perú. Development and pre-clinical evaluation of Newcasle disease virus-vectored SARS-CoV-2 intranasal vaccine candidate. bioRxiv preprint;2021. https://doi.org/10.1101/2021.03.07.434276.

Dahlan MS. Statistik untuk kedokteran dan kesehatan deskriptif, bivariat dan multivariat. Dilengkapi aplikasi menggunakan SPSS Edisi 6. Jkarta : Salemba Medika; 2014.

Olvera DPR, Gutiérrez CC. Multifunctional activity of the β-defensin-2 during respiratory infections. In: Immune response activation and immunomodulation. Tyagi RK, Bisen PS, editor. IntechOpen; 2019. DOI: 10.5772/intechopen.80611.

Wei HX, Wang B, Li B. IL-10 and IL-22 in mucosal immunity: driving protection and pathology. Front Immunol 2020;11:1315. doi: 10.3389/fimmu.2020.01315.

Moyat M, Bouzourene H, Ouyang W, Iovanna J, Renauld JC, Velin D. IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice. Mucosal Immunol 2017;10:271-81. doi: 10.1038/mi.2016.38.

Yang H, Kim DS. Peptide immunotherapy in vaccine development: from epitope to adjuvant. Adv Protein Chem Struct Biol 2015;99:1-14. doi: 10.1016/bs.apcsb.2015.03.001.

Stratmann T. Cholera toxin subunit b as adjuvant—an accelerator in protective immunity and a break in autoimmunity. Vaccines 2015;3:579–96. doi: 10.3390/vaccines3030579.

Leung JM, Davenport M, Wolff MJ, et al. IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 2014;7: 124–33. https://doi.org/10.1038/mi.2013.31.

Gentile MA, Melchiorre S, Emolo C, et al. Structural and functional characterization of the Streptococcus pneumoniae RrgB pilus backbone D1 domain. J Biol Chem 2011; 286: 14588–97. doi: 10.1074/jbc.M110.202739.